Neither K + channels nor PI3K/Akt mediates the vasodilative effect of nebivolol on different types of rat arteries

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 14, Issue 4, 2009, Pages 332-338

  Wang, Yan ^a   Zhang, Mingsheng ^a   Liu, Yu ^a   Li, Jie ^a   Song, Erfei ^a   Niu, Longgang ^a   Cheng, Niuliang ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

Nebivolol; PI3K AKT; Potassium channels; Rat artery

Indexed keywords

1L 6 HYDROXYMETHYL CHIRO INOSITOL 2 2 O METHYL 3 O OCTADECYLCARBONATE; 4 AMINOPYRIDINE; BARIUM CHLORIDE; GLIBENCLAMIDE; IBERIOTOXIN; N(G) NITROARGININE METHYL ESTER; NEBIVOLOL; PHENYLEPHRINE; PHOSPHATIDYLINOSITOL 3 KINASE; POTASSIUM CHANNEL; POTASSIUM CHLORIDE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; UNCLASSIFIED DRUG; WORTMANNIN;

ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY CONSTRICTION; ARTICLE; CAROTID ARTERY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; EXPOSURE; FEMORAL ARTERY; MALE; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL ARTERY; SIGNAL TRANSDUCTION; VASODILATATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ARTERIES; BENZOPYRANS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOLAMINES; MALE; NITRIC OXIDE SYNTHASE TYPE III; POTASSIUM CHANNEL BLOCKERS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; VASODILATION; VASODILATOR AGENTS;

EID: 70449657424     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248409350138     Document Type: Article

References (27)

1. Van Bortel LM, Fici F., Mascagni F. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. Am J Cardiovasc Drugs. 2008 ; 8 (1). 35-44.
2. Gupta S., Harold MW Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide. Cardiovasc Ther. 2008 ; 26 (3). 189-202.
3. Tzemos N., Lim PO, MacDonald TM Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double blind, crossover study. Circulation. 2001 ; 104 (5). 511-514.
4. Weiss R. Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation. Vasc Health Risk Manag. 2006 ; 2 (3). 303-308. (Pubitemid 44275465)
5. Ignarro LJ Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker. Blood Press Suppl. 2004 ; 1: 2-16.
6. Dawes M., Brett SE, Chowienczyk PJ, Mant TG, Ritter JM The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol. 1999 ; 48 (3). 460-463.
7. Ladage D., Brixius K., Hoyer H., et al. Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells. Clin Exp Pharmacol Physiol. 2006 ; 33 (8). 720-724.
8. Fulton D., Gratton JP, McCabe TJ, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999 ; 399 (6736). 597-601.
9. Luo Z., Fujio Y., Kureishi Y., et al. Acute modulation of endothelial Akt/PKB activity alters nitric oxide-dependent vasomotor activity in vivo. J Clin Invest. 2000 ; 106 (4). 493-499.
10. Ferrer M., Marin J., Encabo A., Alonso MJ, Balfagon G. Role of K+ channels and sodium pump in the vasodilation induced by acetylcholine, nitric oxide, and cyclic GMP in the rabbit aorta. Gen Pharmacol. 1999 ; 33 (1). 35-41. (Pubitemid 29292430)
11. Satake N., Shibata M., Shibata S. The involvement of KCa, KATP and KV channels in vasorelaxing responses to acetylcholine in rat aortic rings. Gen Pharmacol. 1997 ; 28 (3). 453-457.
12. Bolotina VM, Najibi S., Palacino PJ, Pagano PJ, Cohen RA Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature. 1994 ; 368 (6474). 850-853.
13. Cowan CL, Palacino JJ, Najibi S., Cohen RA Potassium channel-mediated relaxation to acetylcholine in rabbit arteries. J Pharmacol Exp Ther. 1993 ; 266 (3). 1482-1489.
14. Altwegg LA, dĝUscio LV, Barandier C., Cosentino F., Yang Z., L?1/4scher TF Nebivolol induces NO-mediated relaxations of rat small mesenteric but not of large elastic arteries. J Cardiovasc Pharmacol. 2000 ; 36 (3). 316-320.
15. Kozlovski VI, Lomnicka M., Chlopicki S. Nebivolol and carvedilol induce NO-dependent coronary vasodilatation that is unlikely to be mediated by extracellular ATP in the isolated guinea pig heart. Pharmacol Rep. 2006 ; 58 (suppl): 103-110.
16. Chlopicki S., Kozlovski VI, Gryglewski RJ No-dependent vasodilation induced by nebivolol in coronary circulation is not mediated by beta-adrenoceptors or by 5 HT1A-receptors. J Physiol Pharmacol. 2002 ; 53 (4 pt 1). 615-624.
17. Tran Quang T., Rozec B., Audigane L., Gauthier C. Investigation of the different adrenoceptor targets of nebivolol enantiomers in rat thoracic aorta. Br J Pharmacol. 2009 ; 156 (4). 601-608.
18. Michell BJ, Griffiths JE, Mitchelhill KI, et al. The Akt kinase signals directly to endothelial nitric oxide synthase. Curr Biol. 1999 ; 9 (15). 845-848.
19. Ferro A., Coash M., Yamamoto T., Rob J., Ji Y., Queen L. Nitric oxide-dependent beta2-adrenergic dilatation of rat aorta is mediated through activation of both protein kinase A and Akt. Br J Pharmacol. 2004 ; 143 (3). 397-403.
20. Santhanam AV, Viswanathan S., Dikshit M. Activation of protein kinase B/Akt and endothelial nitric oxide synthase mediates agmatine-induced endothelium-dependent relaxation. Eur J Pharmacol. 2007 ; 572 (2-3). 189-196.
21. Brouet A., Sonveaux P., Dessy C., Balligand JL, Feron O. Hsp90 ensures the transition from the early Ca2+dependent to the late phosphorylation dependent activation of the endothelial nitric-oxide synthase in vascular endothelial growth factor-exposed endothelial cells. J Biol Chem. 2001 ; 276 (35). 32663-32669.
22. Brouet A., Sonveaux P., Dessy C., Moniotte S., Balligand JL, Feron O. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res. 2001 ; 89 (10). 866-873.
23. Dessy C., Saliez J., Ghisdal P., et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation. 2005 ; 112 (8). 1198-1205.
24. Maffei A., Vecchione C., Aretini A., et al. Characterization of nitric oxide release by nebivolol and its metabolites. Blood Vessels. 2006 ; 19 (6). 579-586.
25. Cairrao E., Alvarez E., Santos-Silva AJ, Verde I. Potassium channels are involved in testosterone-induced vasorelaxation of human umbilical artery. Naunyn Schmiedebergs Arch Pharmacol. 2008 ; 376 (5). 375-383.
26. Deenadayalu VP, White RE, Stallone JN, Gao X., Garcia AJ Testosterone relaxes coronary arteries by opening the large-conductance, calcium-activated potassium channel. Am J Physiol Heart Circ Physiol. 2001 ; 281 (4). H1720 - H1727.
27. Georgescua A., Pluteanub F., Flontab ML, Badilac E., Dorobantuc M., Popova D. The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery. Eur J Pharmacol. 2005 ; 508 (1-3). 159-166.